Kimihiko Ito

6PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 05, 2026
Clinicopathologic features and outcomes of patients with microsatellite instability-high endometrial cancer treated with pembrolizumab in Japan: the KCOG-G1902S/1903S study.

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Nov 17, 2025
Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study).

Fuminori Ito, Mototsugu Shimokawa, Atsushi Sugiura

|Oct 25, 2024
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.

Mika Okazawa-Sakai, Shunsuke A Sakai, Ichinosuke Hyodo

|Feb 26, 2022
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.

Tomomi Egawa-Takata, Yutaka Ueda, Kimihiko Ito

|Sep 02, 2021
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata

Pageof 1

Frequent Collaborators

3 joint publications

You Hayasaki

3 joint publications

Tomomi Egawa-Takata

3 joint publications

Hidemichi Watari

3 joint publications

Kosei Hasegawa